Mitoxantrone in advanced renal cancer: a phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
作者信息
van Oosterom A T, Fosså S D, Pizzocaro G, Bergerat J P, Bono A V, De Pauw M, Sylvester R
出版信息
Eur J Cancer Clin Oncol. 1984 Oct;20(10):1239-41. doi: 10.1016/0277-5379(84)90253-0.
PMID:6541582
Abstract
Mitoxantrone at a dose of 15 mg/m2 i.v. q 3 weeks failed to produce responses in 29 adequately treated patients with measurable advanced renal cell carcinoma. The side-effects observed in this group of patients with a good performance status were generally mild. On the basis of this negative result, the application of mitoxantrone in this disease is not recommended.
摘要
Zotero 插件